Our Recommendations
New Publications
- NTDs Part 1: Buruli Ulcer, Chagas, Leishmaniasis (2024)
- Consulta técnica regional OPS/MSF sobre Organización y estructura de la atención médica del enfermo o infectado por Trypanosoma cruzi (enfermedad de Chagas) (2005)
- Chagas Disease Treatment Market Huge Growth in Future Scope 2023-2030 (2023)
- Reimagining the fight against Chagas disease (2020)
- An Update on the Knowledge of Parasite–Vector Interactions of Chagas Disease (2022)
Filter
31
Featured
Recommendations
3
New Publications
1
Language
Document type
Guidelines
11
Studies & Reports
7
Fact sheets
5
Resource Platforms
3
Manuals
2
Strategic & Response Plan
2
No document type
1
Countries / Regions
Latin America and the Carribbean
12
Global
6
Colombia
4
Mexico
2
USA
2
North America
2
Bolivia
2
Peru
1
Venezuela
1
Western Pacific Region
1
Western and Central Europe
1
Uruguay
1
Argentina
1
Brazil
1
Ecuador
1
Authors & Publishers
Publication Years
Toolboxes
NTDs
19
Planetary Health
2
Global Health Education
1
MEDBOX Issue Brief no.35: The first issue brief on the NTD Toolbox contains general strategies, roadmaps, key treatment guidelines, reports, and training material on Buruli ulcer, Chagas, and Leishmaniasis.
Coherent Market Insights has announced the addition of Chagas Disease Treatment Market 2023 Forecast Analysis by Types, Applications, Size, Share, Key Players, and Regions. a new research report to its market research archive. The Chagas Disease Treatment Market has been thoroughly researched and an...
Due to the particular Amazonian situation of vectorial transmission based mostly on the wild cycle of Trypanosoma cruzi with diversity of triatomine vectors involved in effective transmission, and the variety of eco-epidemiological situations that facilitate such transmission, the countries of the A...
El presente decálogo expone de manera concisa los aspectos esenciales de la enfermedad y recoge 10 puntos básicos, esquemáticos y orientados a la práctica para la atención pediátrica de la enfermedad de Chagas.
The annual celebration of International Chagas Day on the 14th of April highlights the impact of this disease on the global health scenario.
Providing information, education and communication for key people involved in Chagas disease control
The Information, education and communication (IEC) activities, with the development of contextualized activities for various actors and scenarios about preventative measures and surveillance tools, are essential to increase awareness, reduce biomedical and psychosocial barriers to accessing diagnosi...
About six to seven million people worldwide, mostly in Latin America, are estimated to be infected with
Trypanosoma cruzi, the parasite that causes Chagas disease (WHO data from 2021). Chagas disease is
found mainly in endemic areas of 21 Latin American countries. Chagas disease was once entirely
...
Chagas disease (CD) is endemic in the Americas, being present in 21 countries, where it affects about 6 million
people.(1) With such relevant numbers of people affected and disability adjusted life years lost, CD is a poverty-related
and poverty-promoting disease.
Although data describe a relevan...
DOI: 10.5772/intechopen.102891Little progress has been made since the 1960s and 19. 70s to widen the therapeutic arsenal against Trypanosoma cruzi, the causative pathogen of Chagas disease, which remains a frustrating and perplexing infectious disease. This chapter focuses on the strategic and opera...
This review focusses on the interactions between the etiologic agent of Chagas disease, Trypanosoma cruzi, and its triatomine vector. The flagellate mainly colonizes the intestinal tract of the insect. The effect of triatomines on trypanosomes is indicated by susceptibility and refractoriness phenom...
La transmisión de T. cruzi de un donante con la enfermedad de Chagas a un receptor de trasplante es poco frecuente y es resultado de la aplicación de un tratamiento quirúrgido. En este documento se proponen diez pautas para manejar y prevenir la transmisión de la enfermedad de Chagas por traspla...
Enfermedad de Chagas e inmunosupresión. Decálogo para la prevención, el diagnóstico y el tratamiento
Según las estimaciones, en las Américas hay entre 6 y 8 millones de personas con infección por T. cruzi, con aproximadamente 30 000 casos nuevos por año por transmisión vectorial, y 8000 casos nuevos anuales por transmisión congénita. Es decir, cerca de 65 millones de personas viven en la Reg...
This manual provides a framework for morbidity management and disability prevention of patients affected by NIDs and gives specific guidance for the proper care of patients suffering from chronic conditions caused by lymphatic filariasis, leprosy, trachoma, and Chagas disease. It is intended to be u...
A systematic review of clinical and observational antiparasitic treatment studies to assess the potential for establishing an individual participant-level data platform.
Chagas disease (CD), caused by the parasite Trypanosoma cruzi, affects ~6–7 million people worldwide. Significant limitations s...
Chagas disease is a tropical parasitic infection transmitted by crawling, blood-sucking insects (kissing bugs). You may have flu-like symptoms or none at all. But the disease can lead to life-threatening complications. With prompt treatment, most people with Chagas disease, also known as American tr...
Bug bites are irritating, and some can be harmful. Learn to identify the type of bug bite and when to seek emergency medical care.
Chagas disease, which is caused by infection with the parasite Trypanosoma cruzi, is known as the silent disease. An estimated 8 million people have the disease and most of them do not know that they are infected.
Chagas disease is caused by Trypanosoma cruzi, a protozoal organism primarily transmitted by triatomine insect vectors, also known as “kissing bugs.” It is a zoonotic disease originally described by Brazilian physician Dr. Carlos Chagas in 1909 and is widespread in Latin America. Although triato...
Chagas disease affects approximately 6 million people, mainly in Latin America. Less than 1% of affected individuals receive proper antiparasitic treatment, and current drugs are inadequate to fight the entire spectrum of the disease. Against this background, Novartis is pursuing an end-to-end appro...
En el presente documento se comunica el progreso logrado en la Región hacia la eliminación de la transmisión maternoinfantil del VIH y la sífilis entre los años 2010 y 2017. Se trata también del primer informe regional sobre la eliminación de la transmisión maternoinfantil y durante la prime...
